Document is current
Any future updates will be listed below
-
Authors
Chen, Jiaqi
Liang, Xiaoting
Han, Qian
He, Haiwei
Huang, Xinran
Shen, Ying
Qiu, Jie
Lin, Fang
Mai, Cong
Li, Ziqi
Ma, Kexin
Hu, Bei
Li, Xin
Zhang, Yuelin https://orcid.org/0000-0002-0065-1116
-
Funding
Funding for this research was provided by:
National Natural Science Grant of China (82270253, 82072225, 82072139, 82170073)
the Natural Science Foundation for Distinguished Scholars of Guangdong Province (20022B1515020104)
the Foundation for Distinguished Scholars of Guangdong Provincial People’s Hospital (KY0120220132)
Natural Science Foundation of Guangdong Province (20022A1515012501)
Natural Science Foundation of Shanghai (24ZR1459300)
National key research and development program intergovernmental key projects (2023YFE0114300)
- License Information
-
More Information
Article History
Received: 9 January 2025
Accepted: 14 May 2025
First Online: 3 June 2025
Declarations
:
: All cell cultures in this study were reviewed and approved by the Ethics Committees of Tongji University (Approved project: mesenchymal stem cell-based therapy for myocardial infarction, Approval No. 2016–050, Date of approval: Sep 18, 2016). Written informed consents were obtained from patients and their families for participation in the study and the use of samples. All animal procedures were performed in accordance with the ARRIVE guidelines and approved by the Animal Research Committee of Guangdong Provincial People’s Hospital (Approved project: Study on the effect and mechanism of iPSC-MSCs exosomal miR-202-5p on the improvement of myocardial infarction by inhibiting the activation of NLRP3 inflammasome. Approval No.KY-Z-2022–348-01, Date of approval: Nov 28, 2022).
: All authors have read and approved the final version of the manuscript and consent to its publication.
: The authors declared no competing interest.
